메뉴 건너뛰기




Volumn 36, Issue 6, 2012, Pages 664-671

Evolution of clinical trial endpoints in chronic myeloid leukemia: Efficacious therapies require sensitive monitoring techniques

Author keywords

Chronic myeloid leukemia; Dasatinib; Endpoints; Imatinib; Molecular monitoring; Nilotinib; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; BOSUTINIB; CYTARABINE; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

EID: 84859871645     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.02.027     Document Type: Review
Times cited : (7)

References (56)
  • 1
    • 58149398623 scopus 로고    scopus 로고
    • Translation of the Philadelphia chromosome into therapy for CML
    • Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112:4808-4817.
    • (2008) Blood , vol.112 , pp. 4808-4817
    • Druker, B.J.1
  • 2
    • 68549125412 scopus 로고    scopus 로고
    • Chronic myelogenous leukemia, BCR-ABL1+
    • Vardiman J.W. Chronic myelogenous leukemia, BCR-ABL1+. Am J Clin Pathol 2009, 132:250-260.
    • (2009) Am J Clin Pathol , vol.132 , pp. 250-260
    • Vardiman, J.W.1
  • 3
    • 34249074686 scopus 로고    scopus 로고
    • Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial
    • Kantarjian H., Pasquini R., Hamerschlak N., Rousselot P., Holowiecki J., Jootar S., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007, 109:5143-5150.
    • (2007) Blood , vol.109 , pp. 5143-5150
    • Kantarjian, H.1    Pasquini, R.2    Hamerschlak, N.3    Rousselot, P.4    Holowiecki, J.5    Jootar, S.6
  • 4
    • 77953725855 scopus 로고    scopus 로고
    • Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
    • Kantarjian H., Shah N.P., Hochhaus A., Cortes J., Shah S., Ayala M., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
    • (2010) N Engl J Med , vol.362 , pp. 2260-2270
    • Kantarjian, H.1    Shah, N.P.2    Hochhaus, A.3    Cortes, J.4    Shah, S.5    Ayala, M.6
  • 5
    • 36348968931 scopus 로고    scopus 로고
    • Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
    • Kantarjian H.M., Giles F., Gattermann N., Bhalla K., Alimena G., Palandri F., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110:3540-3546.
    • (2007) Blood , vol.110 , pp. 3540-3546
    • Kantarjian, H.M.1    Giles, F.2    Gattermann, N.3    Bhalla, K.4    Alimena, G.5    Palandri, F.6
  • 6
    • 10744233716 scopus 로고    scopus 로고
    • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    • O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
    • (2003) N Engl J Med , vol.348 , pp. 994-1004
    • O'Brien, S.G.1    Guilhot, F.2    Larson, R.A.3    Gathmann, I.4    Baccarani, M.5    Cervantes, F.6
  • 7
  • 8
    • 84859861616 scopus 로고    scopus 로고
    • The ongoing evolution of clinical endpoints in oncology
    • McCain J.A. The ongoing evolution of clinical endpoints in oncology. Manag Care 2010, 19:1-11.
    • (2010) Manag Care , vol.19 , pp. 1-11
    • McCain, J.A.1
  • 9
    • 84859813262 scopus 로고    scopus 로고
    • Food and Drug Administration. Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics. Available at: [accessed 26.06.11].
    • Food and Drug Administration. Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics, 2007. Available at: [accessed 26.06.11]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf.
    • (2007)
  • 11
    • 84859862016 scopus 로고    scopus 로고
    • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Chronic Myelogenous Leukemia (Version 2.2012). © National Comprehensive Cancer Network, Inc. Available at: NCCN.org.
    • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Chronic Myelogenous Leukemia (Version 2.2012). © 2012 National Comprehensive Cancer Network, Inc. Available at: NCCN.org.
    • (2012)
  • 12
    • 70350717760 scopus 로고    scopus 로고
    • How I monitor residual disease in chronic myeloid leukemia
    • Radich J.P. How I monitor residual disease in chronic myeloid leukemia. Blood 2009, 114:3376-3381.
    • (2009) Blood , vol.114 , pp. 3376-3381
    • Radich, J.P.1
  • 13
    • 41449106741 scopus 로고    scopus 로고
    • Monitoring treatment of chronic myeloid leukemia
    • Baccarani M., Pane F., Saglio G. Monitoring treatment of chronic myeloid leukemia. Haematologica 2008, 93:161-169.
    • (2008) Haematologica , vol.93 , pp. 161-169
    • Baccarani, M.1    Pane, F.2    Saglio, G.3
  • 14
    • 67749122513 scopus 로고    scopus 로고
    • Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia
    • Foroni L., Gerrard G., Nna E., Khorashad J.S., Stevens D., Swale B., et al. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia. American Journal of Hematology 2009, 84:517-522.
    • (2009) American Journal of Hematology , vol.84 , pp. 517-522
    • Foroni, L.1    Gerrard, G.2    Nna, E.3    Khorashad, J.S.4    Stevens, D.5    Swale, B.6
  • 15
    • 73349122639 scopus 로고    scopus 로고
    • Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
    • Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
    • (2009) J Clin Oncol , vol.27 , pp. 6041-6051
    • Baccarani, M.1    Cortes, J.2    Pane, F.3    Niederwieser, D.4    Saglio, G.5    Apperley, J.6
  • 16
    • 10744229080 scopus 로고    scopus 로고
    • Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
    • Hughes T.P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M.L., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423-1432.
    • (2003) N Engl J Med , vol.349 , pp. 1423-1432
    • Hughes, T.P.1    Kaeda, J.2    Branford, S.3    Rudzki, Z.4    Hochhaus, A.5    Hensley, M.L.6
  • 17
    • 33745603988 scopus 로고    scopus 로고
    • Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
    • Hughes T.P., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37.
    • (2006) Blood , vol.108 , pp. 28-37
    • Hughes, T.P.1    Deininger, M.2    Hochhaus, A.3    Branford, S.4    Radich, J.5    Kaeda, J.6
  • 18
    • 0027164941 scopus 로고
    • Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group
    • Hehlmann R., Heimpel H., Hasford J., Kolb H.J., Pralle H., Hossfeld D.K., et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 1993, 82:398-407.
    • (1993) Blood , vol.82 , pp. 398-407
    • Hehlmann, R.1    Heimpel, H.2    Hasford, J.3    Kolb, H.J.4    Pralle, H.5    Hossfeld, D.K.6
  • 19
    • 23444462074 scopus 로고
    • Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia
    • Italian Cooperative Study Group on Chronic Myeloid Leukemia
    • Italian Cooperative Study Group on Chronic Myeloid Leukemia Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med 1994, 330:820-825.
    • (1994) N Engl J Med , vol.330 , pp. 820-825
  • 20
    • 0029154919 scopus 로고
    • A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase
    • Ohnishi K., Ohno R., Tomonaga M., Kamada N., Onozawa K., Kuramoto A., et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995, 86:906-916.
    • (1995) Blood , vol.86 , pp. 906-916
    • Ohnishi, K.1    Ohno, R.2    Tomonaga, M.3    Kamada, N.4    Onozawa, K.5    Kuramoto, A.6
  • 22
    • 75749105885 scopus 로고    scopus 로고
    • Phase III, randomized, open-label study of daily imatinib mesylate 400mg versus 800mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study
    • Cortes J.E., Baccarani M., Guilhot F., Druker B.J., Branford S., Kim D.W., et al. Phase III, randomized, open-label study of daily imatinib mesylate 400mg versus 800mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010, 28:424-430.
    • (2010) J Clin Oncol , vol.28 , pp. 424-430
    • Cortes, J.E.1    Baccarani, M.2    Guilhot, F.3    Druker, B.J.4    Branford, S.5    Kim, D.W.6
  • 23
    • 21144451094 scopus 로고    scopus 로고
    • In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
    • O'Hare T., Walters D.K., Stoffregen E.P., Jia T., Manley P.W., Mestan J., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500-4505.
    • (2005) Cancer Res , vol.65 , pp. 4500-4505
    • O'Hare, T.1    Walters, D.K.2    Stoffregen, E.P.3    Jia, T.4    Manley, P.W.5    Mestan, J.6
  • 25
    • 79251546724 scopus 로고    scopus 로고
    • Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
    • Kantarjian H.M., Giles F.J., Bhalla K.N., Pinilla-Ibarz J., Larson R.A., Gattermann N., et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011, 117:1141-1145.
    • (2011) Blood , vol.117 , pp. 1141-1145
    • Kantarjian, H.M.1    Giles, F.J.2    Bhalla, K.N.3    Pinilla-Ibarz, J.4    Larson, R.A.5    Gattermann, N.6
  • 26
    • 83855164150 scopus 로고    scopus 로고
    • Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase
    • Nicolini F.E., Turkina A., Shen Z.X., Gallagher N., Jootar S., Powell B.L., et al. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. Cancer 2011, 118:118-126.
    • (2011) Cancer , vol.118 , pp. 118-126
    • Nicolini, F.E.1    Turkina, A.2    Shen, Z.X.3    Gallagher, N.4    Jootar, S.5    Powell, B.L.6
  • 27
    • 70349306853 scopus 로고    scopus 로고
    • Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value
    • Hochhaus A., Muller M.C., Radich J., Branford S., Kantarjian H.M., Hanfstein B., et al. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia 2009, 23:1628-1633.
    • (2009) Leukemia , vol.23 , pp. 1628-1633
    • Hochhaus, A.1    Muller, M.C.2    Radich, J.3    Branford, S.4    Kantarjian, H.M.5    Hanfstein, B.6
  • 28
    • 70149105272 scopus 로고    scopus 로고
    • Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)
    • Kantarjian H., Pasquini R., Levy V., Jootar S., Holowiecki J., Hamerschlak N., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009, 115:4136-4147.
    • (2009) Cancer , vol.115 , pp. 4136-4147
    • Kantarjian, H.1    Pasquini, R.2    Levy, V.3    Jootar, S.4    Holowiecki, J.5    Hamerschlak, N.6
  • 29
    • 80055070888 scopus 로고    scopus 로고
    • Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive CML patients with resistance or intolerance to imatinib
    • Cortes J.E., Kantarjian H.M., Brummendorf T.H., Kim D.W., Turkina A.G., Shen Z.X., et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive CML patients with resistance or intolerance to imatinib. Blood 2011, 118:4567-4576.
    • (2011) Blood , vol.118 , pp. 4567-4576
    • Cortes, J.E.1    Kantarjian, H.M.2    Brummendorf, T.H.3    Kim, D.W.4    Turkina, A.G.5    Shen, Z.X.6
  • 30
    • 73949145209 scopus 로고    scopus 로고
    • Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia
    • Rosti G., Palandri F., Castagnetti F., Breccia M., Levato L., Gugliotta G., et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009, 114:4933-4938.
    • (2009) Blood , vol.114 , pp. 4933-4938
    • Rosti, G.1    Palandri, F.2    Castagnetti, F.3    Breccia, M.4    Levato, L.5    Gugliotta, G.6
  • 31
    • 75749090051 scopus 로고    scopus 로고
    • Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase
    • Cortes J.E., Jones D., O'Brien S., Jabbour E., Konopleva M., Ferrajoli A., et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010, 28:392-397.
    • (2010) J Clin Oncol , vol.28 , pp. 392-397
    • Cortes, J.E.1    Jones, D.2    O'Brien, S.3    Jabbour, E.4    Konopleva, M.5    Ferrajoli, A.6
  • 32
    • 79952903358 scopus 로고    scopus 로고
    • Nilotinib 300mg twice daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: updated results of the ICORG 0802 phase 2 study with analysis of the GeneXpert system versus IS BCR-ABL RQ PCR
    • (ASH Annual Meeting Abstracts)
    • Conneally E., Swords R.T., Giles F.J., McMullin M.F., Coutre P.l., Langabeer S., et al. Nilotinib 300mg twice daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: updated results of the ICORG 0802 phase 2 study with analysis of the GeneXpert system versus IS BCR-ABL RQ PCR. Blood 2010, 116:3427. (ASH Annual Meeting Abstracts).
    • (2010) Blood , vol.116 , pp. 3427
    • Conneally, E.1    Swords, R.T.2    Giles, F.J.3    McMullin, M.F.4    Coutre, P.5    Langabeer, S.6
  • 33
    • 80052383499 scopus 로고    scopus 로고
    • Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
    • Kantarjian H.M., Hochhaus A., Saglio G., De Souza Santos F.P., Flinn I.W., Stenke L., et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011, 12:841-851.
    • (2011) Lancet Oncol , vol.12 , pp. 841-851
    • Kantarjian, H.M.1    Hochhaus, A.2    Saglio, G.3    De Souza Santos, F.P.4    Flinn, I.W.5    Stenke, L.6
  • 34
    • 75749129911 scopus 로고    scopus 로고
    • Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia
    • Cortes J.E., Jones D., O'Brien S., Jabbour E., Ravandi F., Koller C., et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010, 28:398-404.
    • (2010) J Clin Oncol , vol.28 , pp. 398-404
    • Cortes, J.E.1    Jones, D.2    O'Brien, S.3    Jabbour, E.4    Ravandi, F.5    Koller, C.6
  • 35
    • 79952787880 scopus 로고    scopus 로고
    • A randomized phase II trial of dasatinib 100mg vs imatinib 400mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 intergroup trial
    • LBA-6 (ASH Annual Meeting Abstracts)
    • Radich J.P., Kopecky K.J., Kamel-Reid S., Stock W., Paietta E., Wadleigh M., et al. A randomized phase II trial of dasatinib 100mg vs imatinib 400mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 intergroup trial. Blood 2010, 116. LBA-6 (ASH Annual Meeting Abstracts).
    • (2010) Blood , vol.116
    • Radich, J.P.1    Kopecky, K.J.2    Kamel-Reid, S.3    Stock, W.4    Paietta, E.5    Wadleigh, M.6
  • 36
    • 79952038795 scopus 로고    scopus 로고
    • Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up
    • (ASH Annual Meeting Abstracts)
    • Shah N., Kantarjian H., Hochhaus A., Cortes J.E., Bradley-Garelik M.B., Zhu C., et al. Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up. Blood 2010, 116:206. (ASH Annual Meeting Abstracts).
    • (2010) Blood , vol.116 , pp. 206
    • Shah, N.1    Kantarjian, H.2    Hochhaus, A.3    Cortes, J.E.4    Bradley-Garelik, M.B.5    Zhu, C.6
  • 37
    • 78650218988 scopus 로고    scopus 로고
    • An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia
    • (ASH Annual Meeting Abstracts)
    • Gambacorti-Passerini C., Kim D.-W., Kantarjian H.M., Brummendorf T.H., Dyagil I., Griskevicius L., et al. An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia. Blood 2010, 116:208. (ASH Annual Meeting Abstracts).
    • (2010) Blood , vol.116 , pp. 208
    • Gambacorti-Passerini, C.1    Kim, D.-W.2    Kantarjian, H.M.3    Brummendorf, T.H.4    Dyagil, I.5    Griskevicius, L.6
  • 38
    • 83755180770 scopus 로고    scopus 로고
    • Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up
    • Gambacorti-Passerini C., Cortes J.E., Kim D., Kantarjian H., Khattry N., Lipton J.H., et al. Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up. ASCO Meeting Abstracts 2011, 29:6509.
    • (2011) ASCO Meeting Abstracts , vol.29 , pp. 6509
    • Gambacorti-Passerini, C.1    Cortes, J.E.2    Kim, D.3    Kantarjian, H.4    Khattry, N.5    Lipton, J.H.6
  • 39
    • 79952038063 scopus 로고    scopus 로고
    • ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)
    • (ASH Annual Meeting Abstracts)
    • Hughes T.P., Hochhaus A., Saglio G., Kim D.-W., Jootar S., Coutre P.l., et al. ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Blood 2010, 116:207. (ASH Annual Meeting Abstracts).
    • (2010) Blood , vol.116 , pp. 207
    • Hughes, T.P.1    Hochhaus, A.2    Saglio, G.3    Kim, D.-W.4    Jootar, S.5    Coutre, P.6
  • 40
    • 83655174011 scopus 로고    scopus 로고
    • Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): two-year follow-up from DASISION
    • Kantarjian H., Shah N.P., Cortes J.E., Baccarani M., Bradley-Garelik M.B., Zhu C., et al. Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): two-year follow-up from DASISION. ASCO Meeting Abstracts 2011, 29:6510.
    • (2011) ASCO Meeting Abstracts , vol.29 , pp. 6510
    • Kantarjian, H.1    Shah, N.P.2    Cortes, J.E.3    Baccarani, M.4    Bradley-Garelik, M.B.5    Zhu, C.6
  • 41
    • 0037441629 scopus 로고    scopus 로고
    • Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis
    • Kantarjian H.M., O'Brien S., Cortes J.E., Shan J., Giles F.J., Rios M.B., et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003, 97:1033-1041.
    • (2003) Cancer , vol.97 , pp. 1033-1041
    • Kantarjian, H.M.1    O'Brien, S.2    Cortes, J.E.3    Shan, J.4    Giles, F.J.5    Rios, M.B.6
  • 42
    • 77949767505 scopus 로고    scopus 로고
    • International randomized study of interferon versus STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib
    • (ASH Annual Meeting Abstracts)
    • Deininger M., O'Brien S.G., Guilhot F., Goldman J.M., Hochhaus A., Hughes T.P., et al. International randomized study of interferon versus STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009, 114:1126. (ASH Annual Meeting Abstracts).
    • (2009) Blood , vol.114 , pp. 1126
    • Deininger, M.1    O'Brien, S.G.2    Guilhot, F.3    Goldman, J.M.4    Hochhaus, A.5    Hughes, T.P.6
  • 43
    • 77958595179 scopus 로고    scopus 로고
    • Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon versus STI571 (IRIS)
    • Hughes T.P., Hochhaus A., Branford S., Muller M.C., Kaeda J.S., Foroni L., et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon versus STI571 (IRIS). Blood 2010, 116:3758-3765.
    • (2010) Blood , vol.116 , pp. 3758-3765
    • Hughes, T.P.1    Hochhaus, A.2    Branford, S.3    Muller, M.C.4    Kaeda, J.S.5    Foroni, L.6
  • 44
    • 79955018499 scopus 로고    scopus 로고
    • Tolerability-adapted imatinib 800mg/d versus 400mg/d versus 400mg/d plus interferon-{alpha} in newly diagnosed chronic myeloid leukemia
    • Hehlmann R., Lauseker M., Jung-Munkwitz S., Leitner A., Muller M.C., Pletsch N., et al. Tolerability-adapted imatinib 800mg/d versus 400mg/d versus 400mg/d plus interferon-{alpha} in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011, 29:1634-1642.
    • (2011) J Clin Oncol , vol.29 , pp. 1634-1642
    • Hehlmann, R.1    Lauseker, M.2    Jung-Munkwitz, S.3    Leitner, A.4    Muller, M.C.5    Pletsch, N.6
  • 45
    • 79952327332 scopus 로고    scopus 로고
    • Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy
    • Hanfstein B., Muller M.C., Kreil S., Ernst T., Schenk T., Lorentz C., et al. Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica 2011, 96:360-366.
    • (2011) Haematologica , vol.96 , pp. 360-366
    • Hanfstein, B.1    Muller, M.C.2    Kreil, S.3    Ernst, T.4    Schenk, T.5    Lorentz, C.6
  • 46
    • 77958577395 scopus 로고    scopus 로고
    • Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: which parameter at which time-point does matter?
    • Kim D.H., Sriharsha L., Jung C.W., Kamel-Reid S., Radich J.P., Lipton J.H. Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: which parameter at which time-point does matter?. Am J Hematol 2010, 85:856-862.
    • (2010) Am J Hematol , vol.85 , pp. 856-862
    • Kim, D.H.1    Sriharsha, L.2    Jung, C.W.3    Kamel-Reid, S.4    Radich, J.P.5    Lipton, J.H.6
  • 47
    • 84859862018 scopus 로고    scopus 로고
    • Kinetics of molecular response with different tyrosine kinase inhibitors (TKI) used as frontline therapy in chronic myeloid leukemia-chronic phase (CML CP)
    • (ASH Annual Meeting Abstracts)
    • Naqvi K., Kantarjian H.M., Luthra R., Jabbour E., O'Brien S., Burton E.M., et al. Kinetics of molecular response with different tyrosine kinase inhibitors (TKI) used as frontline therapy in chronic myeloid leukemia-chronic phase (CML CP). Blood 2011, 118:3784. (ASH Annual Meeting Abstracts).
    • (2011) Blood , vol.118 , pp. 3784
    • Naqvi, K.1    Kantarjian, H.M.2    Luthra, R.3    Jabbour, E.4    O'Brien, S.5    Burton, E.M.6
  • 48
    • 84859857734 scopus 로고    scopus 로고
    • Dasatinib and imatinib-induced reductions in BCR-ABL transcript levels below 10% at 3 months are associated with improved responses in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): analysis of molecular response kinetics in the DASISION trial
    • (ASH Annual Meeting Abstracts)
    • Hochhaus A., Saglio G., Chuah C., Pavlovsky C., Garelick M.B.B., Lambert A., et al. Dasatinib and imatinib-induced reductions in BCR-ABL transcript levels below 10% at 3 months are associated with improved responses in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): analysis of molecular response kinetics in the DASISION trial. Blood 2011, 118:2767. (ASH Annual Meeting Abstracts).
    • (2011) Blood , vol.118 , pp. 2767
    • Hochhaus, A.1    Saglio, G.2    Chuah, C.3    Pavlovsky, C.4    Garelick, M.B.B.5    Lambert, A.6
  • 49
    • 84864233871 scopus 로고    scopus 로고
    • Molecular and cytogenetic response after 3months of imatinib treatment is predictive for the risk of disease progression and death in newly diagnosed chronic myeloid leukemia patients-a follow-up analysis of the German CML Study IV
    • (ASH Annual Meeting Abstracts)
    • Hanfstein B., Muller M.C., Erben P., Lauseker M., Saussele S., Proetel U., et al. Molecular and cytogenetic response after 3months of imatinib treatment is predictive for the risk of disease progression and death in newly diagnosed chronic myeloid leukemia patients-a follow-up analysis of the German CML Study IV. Blood 2011, 118:783. (ASH Annual Meeting Abstracts).
    • (2011) Blood , vol.118 , pp. 783
    • Hanfstein, B.1    Muller, M.C.2    Erben, P.3    Lauseker, M.4    Saussele, S.5    Proetel, U.6
  • 50
    • 78049528573 scopus 로고    scopus 로고
    • Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
    • Mahon F.X., Rea D., Guilhot J., Guilhot F., Huguet F., Nicolini F., et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010, 11:1029-1035.
    • (2010) Lancet Oncol , vol.11 , pp. 1029-1035
    • Mahon, F.X.1    Rea, D.2    Guilhot, J.3    Guilhot, F.4    Huguet, F.5    Nicolini, F.6
  • 52
    • 80355125811 scopus 로고    scopus 로고
    • Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features
    • Ross D.M., Bartley P.A., Goyne J., Morley A.A., Seymour J.F., Grigg A.P. Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features. Haematologica 2011, 96:1720-1722.
    • (2011) Haematologica , vol.96 , pp. 1720-1722
    • Ross, D.M.1    Bartley, P.A.2    Goyne, J.3    Morley, A.A.4    Seymour, J.F.5    Grigg, A.P.6
  • 53
    • 67049087117 scopus 로고    scopus 로고
    • Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
    • Noens L., van Lierde M.A., De Bock R., Verhoef G., Zachee P., Berneman Z., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113:5401-5411.
    • (2009) Blood , vol.113 , pp. 5401-5411
    • Noens, L.1    van Lierde, M.A.2    De Bock, R.3    Verhoef, G.4    Zachee, P.5    Berneman, Z.6
  • 54
    • 77952467377 scopus 로고    scopus 로고
    • Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
    • Marin D., Bazeos A., Mahon F.X., Eliasson L., Milojkovic D., Bua M., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28:2381-2388.
    • (2010) J Clin Oncol , vol.28 , pp. 2381-2388
    • Marin, D.1    Bazeos, A.2    Mahon, F.X.3    Eliasson, L.4    Milojkovic, D.5    Bua, M.6
  • 55
    • 79953823237 scopus 로고    scopus 로고
    • Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
    • Ibrahim A.R., Eliasson L., Apperley J.F., Milojkovic D., Bua M., Szydlo R., et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011, 117:3733-3736.
    • (2011) Blood , vol.117 , pp. 3733-3736
    • Ibrahim, A.R.1    Eliasson, L.2    Apperley, J.F.3    Milojkovic, D.4    Bua, M.5    Szydlo, R.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.